Related Experiment Video
Updated: Jun 2, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Cyclophosphamide-induced symptomatic hyponatraemia
D M Bruining1, E N van Roon, H de Graaf
1Department of Internal Medicine, Medical Centre Leeuwarden, the Netherlands. Martijn.Bruining@ZNB.NL
Abstract:
Cyclophosphamide is an alkylating agent used in antineoplastic and immunosuppressive therapies. Symptomatic hyponatraemia is a rare but life-threatening complication in patients treated with cyclophosphamide. We report the case of a 64-year-old woman with breast cancer who developed severe symptomatic hyponatraemia with a generalised seizure and convulsions after a second cycle of adjuvant chemotherapy with 5-fluouracil, epirubicin and cyclophosphamide. She completely recovered after correction of the serum sodium concentration without neurological deficits. Physicians prescribing cyclophosphamide, irrespective of the treatment indication and dosage, should be aware of this potentially life-threatening complication.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Cryptococcal Meningitis
Hemodialysis II: Procedure and Complications
Hyperosmolar Hyperglycemic State
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Diabetes Insipidus II: Pathophysiology